Notice: The ASA website will be unavailable beginning Thursday, May 17 from 4 p.m. until noon (CDT) on May 18 due to system maintenance.

>

WEBINARS

RSS
>

MEETINGS / EVENTS

RSS

October 13 - 17 2012, 12:00 AM - 12:00 AM

ANESTHESIOLOGY 2012

>

FDA MEDWATCH ALERTS

RSS

May 16, 2012

Hydromorphone Hydrochloride Recall

Summary:

Hydromorphone Hydrochloride Recall

April 18, 2012

Morphine Sulfate Injection USP, 4 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject by Hospira, Inc: Recall - May Contain More Than Intended Fill Volume

Summary:

Customer report of two Carpujects syringes containing more than the 1 mL labeled fill volume. Opioid pain medications such as morphine have life-threatening consequences if overdosed. Those consequences can include respiratory depression (slowed breathing or suspension of breathing), and low blood pressure.

March 05, 2012

Cardiac Science Powerheart, CardioVive, CardioLife; GE Responder and Responder Pro; and Nihon-Kohden Automated External Defibrillators (AEDs): Class I Recall - Defective Component

Summary: FDA notified healthcare professionals and medical care organizations of the Class 1 recall of the listed AEDs which contain a component that may fail unexpectedly due to a defect. If the component were to fail during a rescue attempt, the AED may not deliver defibrillation therapy, causing serious adverse health consequences, including death. The unit’s self test may not detect the failure or impending failure of the component.

>

ASA FEATURED PRODUCT

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-12CE

... Read more »

Single Copies, Member Price: $300

The Joint Commission Adopts ASA Recommendations on Medication Management Issues

Tuesday, May 17, 2011

The Joint Commission has adopted many recommendations on medication management issues suggested in a December 2010 letter from the American Society of Anesthesiologists (ASA), American Association of Nurse Anesthetists (AANA), American Academy of Anesthesiologist Assistants (AAAA) and the Anesthesia Patient Safety Foundation (APSF).

ASA specifically appreciates the following clarifications and modifications made by The Joint Commission:

• Deleting of the NPSG 03.04.01 FAQ prohibiting pre-labeling of syringes. We can agree with a general requirement of syringe labeling while allowing hospitals and providers to determine when and how they meet this standard.

• Clarifying that anesthesia providers may carry appropriate medications on their body as long as the institution has and enforces written policies.

• Clarifying that authorized personnel may be present around unlocked medication carts as long as such carts are located in a secured area and the hospital has and enforces written policies. 

• Clarifying that MM.06.01.01 EP9 with respect to informed consent was intended for medications ordered to treat conditions rather than anesthesia services.  Thus, anesthesiologists are not required to explain all of the possible effects of the dozens of medications that might be used during a surgical procedure as part of the informed consent process.

Click here to read the original December 2010 joint letter signed by ASA.

Click here to read the letter from The Joint Commission adopting some of the recommendations.

 

« Back to Washington Alerts